Interview with Director & Chief Scientific Officer of Moexa Pharmaceuticals, Dr. Stephen Porter

Moexa Pharmaceuticals is a multi national biotech company developing novel therapeutics focusing on the TGF-β/Smad3 signaling pathway. Moexa Pharmaceuticals' drug candidate, Cancelex™, is a novel anti-tumor therapeutic candidate focusing on the TGF-β/Smad3 signaling pathway, which is associated with tumor progression and tumorigenesis. In incidence of cancer, TGF-β Smad3 promotes tumor growth and cancer by suppressing NK cell immunity and promoting Treg response, angiogenesis, and MMPs activities. Targeting the Smad3-dependent tumor microenvironment with an inhibitor that deactivates Smad3 is a novel and effective therapy for cancer, and may be directly applicable to other related diseases involving Smad3 regulation. The therapeutic NMEs of the company demonstrate strong efficacy in pre-clinical tests for cancers, and in preliminary tests for lung fibrosis. Moexa Pharmaceuticals has solid patents in place protecting their IP and seeks collaboration to expand their pipeline as they advance towards clinical trials.

Schedule a call or send us a message
Schedule Call
Contact us